NCI COVID-19 in Cancer Patients, NCCAPS Study

Study summary

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBiospecimen Collection and Data Collection

Plus 2 other study approaches.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 26, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?932 U.S. locations

Locations may change over time.

Who runs it?National Cancer Institute (NCI)

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: National Cancer Institute (NCI)
Interventions being studied: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Metastatic or stage IV→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

NCCAPS STUDY ELIGIBILITY CRITERIA:
Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) and cancer treatment that fits into one of the three following categories:
Metastatic (stage IV) solid tumor, any hematologic malignancy, or any central nervous system (CNS) malignancy, and:
Patient is receiving eligible active treatment (defined as current treatment or treatment within the 6 weeks prior to their first positive SARS-CoV-2 test collection) or is expected to begin receiving treatment within 2 weeks of study enrollment
Eligible active treatment types are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, radiation therapy, or targeted radionuclide therapy; OR
Non-metastatic (Stage I-III) solid tumor and:
Patient is receiving eligible active treatment (defined as current treatment or treatment within past 6 weeks prior to their first positive SARS-CoV-2 test collection) or is expected to begin receiving treatment within 2 weeks of study enrollment
Eligible active treatment types for non-metastatic solid tumor patients are intravenous chemotherapy, immunotherapy, targeted therapy, radiation therapy, targeted radionuclide therapy, or monoclonal antibody therapy (except as noted below)
HER2-targeted therapy (trastuzumab, pertuzumab, neratinib, ado-trastuzumab) that is not accompanied by chemotherapy is NOT considered an eligible active treatment
Patients on endocrine therapy alone are not eligible; OR
Prior or current transplant for the treatment of cancer:
Patient has received an allogenic stem cell/bone marrow transplant or chimeric antigen receptor (CAR)-T cell or other modified cellular therapy at any time; or
Patient is currently receiving treatment or prophylaxis for graft versus (vs.) host disease; or
Patient has received an autologous stem cell/bone marrow transplant within the past 2 years
Patient must have documented positive viral test result for SARS-CoV-2
For patients 18 years of age or older, the specimen collection for the patient's FIRST positive test must have occurred no earlier than 14 days prior to enrollment
For patients under 18 years of age, the specimen collection for the patient's first positive test must have occurred after January 31, 2020
The viral test can be either a nucleic acid (polymerase chain reaction \[PCR\]) test or an antigen test. Serological or antibody tests are not allowed
Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the viral SARS-CoV-2 test
Patients with prior negative viral SARS-CoV-2 test(s) are eligible if they are being tested again
The SARS-CoV-2 test must be a validated diagnostic assay performed in accordance with the most recent guidance issued by the Food and Drug administration (FDA) in the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency. This policy is available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised
Human immunodeficiency virus (HIV)-infected patients are eligible
Patients with CNS metastases are eligible
Co-enrollment on other clinical trials (for cancer or for COVID-19) is allowed
PEDIATRIC COVNET COHORT ELIGIBILITY CRITERIA: Patients should only be enrolled in the pediatric COVNET cohort if they are not eligible for the main NCCAPS Study cohort or decline to participate in the main study
Patient must be \< 18 years of age
Patient must have a positive SARS-CoV-2 viral test after January 31, 2020
Patient must have a current or prior diagnosis of cancer. Active cancer treatment is not required
Note: Patients who enroll on Pediatric COVNET cohort will not be followed longitudinally; study data collection involves only a single questionnaire and research blood collection. A separate consent document is provided for the Pediatric COVNET cohort

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Alabama at Birmingham Cancer CenterBirmingham, Alabama
Veterans Administration Medical Center - BirminghamBirmingham, Alabama
USA Health Strada Patient Care CenterMobile, Alabama
Anchorage Associates in Radiation MedicineAnchorage, Alaska
Anchorage Radiation Therapy CenterAnchorage, Alaska
Alaska Breast Care and Surgery LLCAnchorage, Alaska
Alaska Oncology and Hematology LLCAnchorage, Alaska
Alaska Women's Cancer CareAnchorage, Alaska
Anchorage Oncology CentreAnchorage, Alaska
Katmai Oncology GroupAnchorage, Alaska
Providence Alaska Medical CenterAnchorage, Alaska
Fairbanks Memorial HospitalFairbanks, Alaska

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 26, 2026. Always confirm current availability with the study team.

View original record ↗